DCTH vs. BWAY, APEN, EMBC, PLSE, FNA, SRDX, SIBN, OFIX, IRMD, and BVS
Should you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include BrainsWay (BWAY), Apollo Endosurgery (APEN), Embecta (EMBC), Pulse Biosciences (PLSE), Paragon 28 (FNA), Surmodics (SRDX), SI-BONE (SIBN), Orthofix Medical (OFIX), Iradimed (IRMD), and Bioventus (BVS). These companies are all part of the "surgical & medical instruments" industry.
Delcath Systems (NASDAQ:DCTH) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, community ranking, risk, institutional ownership, earnings, dividends and analyst recommendations.
BrainsWay has higher revenue and earnings than Delcath Systems. BrainsWay is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
BrainsWay has a net margin of -4.83% compared to Delcath Systems' net margin of -1,080.72%. BrainsWay's return on equity of -3.98% beat Delcath Systems' return on equity.
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 30.1% of BrainsWay shares are owned by institutional investors. 17.9% of Delcath Systems shares are owned by company insiders. Comparatively, 19.0% of BrainsWay shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Delcath Systems presently has a consensus target price of $20.20, indicating a potential upside of 186.52%. BrainsWay has a consensus target price of $13.00, indicating a potential upside of 106.68%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts clearly believe Delcath Systems is more favorable than BrainsWay.
BrainsWay received 39 more outperform votes than Delcath Systems when rated by MarketBeat users. Likewise, 64.58% of users gave BrainsWay an outperform vote while only 22.33% of users gave Delcath Systems an outperform vote.
In the previous week, BrainsWay had 1 more articles in the media than Delcath Systems. MarketBeat recorded 4 mentions for BrainsWay and 3 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.75 beat BrainsWay's score of 1.53 indicating that Delcath Systems is being referred to more favorably in the media.
Delcath Systems has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
Summary
BrainsWay beats Delcath Systems on 11 of the 18 factors compared between the two stocks.
Get Delcath Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Delcath Systems Competitors List
Related Companies and Tools
